EFFECTS OF FENOFIBRATE AND XUEZHIKANG ON HIGH‐FAT DIET‐INDUCED NON‐ALCOHOLIC FATTY LIVER DISEASE
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
1. Fenofibrate and xuezhikang are two types of drugs widely used in the treatment of dyslipidaemia in China. The main purpose of present study was to test the efficacies and explore the potential mechanisms of action of the two lipid-lowering agents on high-fat diet-induced non-alcoholic fatty liver disease (NAFLD). 2. Rats were randomly divided into four groups, with eight rats per group. One group was given normal diet, whereas the other three groups were fed a high-fat diet. Forty-two days later, two of the high-fat diet-fed groups were administered fenofibrate (100 mg/kg, p.o.) and xuezhikang (300 mg/kg, p.o.) for another 42 consecutive days. The other two groups were administered placebo (saline) by gavage. 3. Typical pathological symptoms of NAFLD occurred in the high-fat diet groups. Fenofibrate and xuezhikang treatment markedly improved NAFLD, ameliorating dyslipidaemia and fat accumulation in the liver, improving insulin resistance and ameliorating oxidative stress. Hepatic steatosis, necro-inflammation and collagen deposition were lessened in the drug-treated groups. However, both xuezhikang and fenofibrate failed to reverse hepatomegaly and fenofibrate even aggravated it. Xuezhikang reversed aminotransferase abnormalities, but fenofibrate had less of an effect. 4. The common therapeutic mechanism of action of fenofibate and xuezhikang likely involves inhibition of the hepatic expression of tumour necrosis factor-alpha. Fenofibrate upregulated mRNA levels of peroxisome proliferator-activated receptor (PPAR) alpha in the liver, whereas xuezhikang had no effect on the hepatic expression of PPARalpha and this may explain, in part, their different effects on the NAFLD rats. 5. The results suggest that fenofibrate and xuezhikang may have potential clinical application in the treatment of NAFLD. However, the side-effects of fenofibrate and the underlying constituents of xuezhikang need to be determined and investigated further.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protection from obesity-induced insulin resistance in mice lacking TNF-α function
Uysal, K. T., Wiesbrock, S. M., Marino, M. W., & Hotamisligil, G. S. (1997) · Nature · doi:10.1038/39335 · Cited by 2,234 · cited 1×
“Tumour necrosis factor-a inhibits the propagation of insulin receptor-initiated signals in hepatocytes and is known to promote insulin resistance and steatohepatitis in ob/ob mice and in NAFLD patients.(33,34) The present study first demonstrated that xuezhikang inhibited TNF-a mRNA expression, improved insulin resist…”
BackgroundLee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322 · cited 1×
“Insulin resistance provokes fat accumulation in the liver and accelerates the formation of hepatic steatosis.(25) Insulin resistance also exacerbates steatohepatitis and liver fibrosis by regulating some cytokines (including the interleukins, the TNF family, interferons and chemokines).”
BackgroundEvaluation of Abnormal Liver-Enzyme Results in Asymptomatic Patients
Pratt, D. S., & Kaplan, M. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004273421707 · Cited by 1,203
Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089
Guerre-Millo, M., Gervois, P., Raspé, E., Madsen, L., Poulain, P., Derudas, B., Herbert, J.-M., Winegar, D. A., Willson, T. M., Fruchart, J.-C., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.22.16638 · Cited by 605
Ip, E., Farrell, G., Hall, P., Robertson, G., & Leclercq, I. (2004) · Hepatology · doi:10.1002/hep.20170 · Cited by 383
Cited by
Fabbrini, E., Mohammed, B. S., Korenblat, K. M., Magkos, F., McCrea, J., Patterson, B. W., & Klein, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2622 · Cited by 192
Lê, K.-A., & Bortolotti, M. (2008) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328302f3ec · Cited by 60
Hashim, Y., Abdel Baky, N., Kamal, M., & Gad, A. (2021) · Azhar International Journal of Pharmaceutical and Medical Sciences · doi:10.21608/aijpms.2021.54231.1028
Metadata
- Authors
- Hong, X. Z., Li, L. D., & Wu, L. M.
- Venue
- Clinical and Experimental Pharmacology and Physiology
- Publisher
- Wiley
- Published
- 2006-12-13
- Volume
- 34
- Issue
- 1-2
- Pages
- 27-35
- ISSN
- 0305-1870 (ISSN-L)
- 1440-1681
- OpenAlex
- W2042510973
- Cited by
- 54
- References
- 7
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EFFECTS OF FENOFIBRATE AND XUEZHIKANG ON HIGH‐FAT DIET‐INDUCED NON‐ALCOHOLIC FATTY LIVER DISEASE. https://app.cochat.ai/papers/10.1111/j.1440-1681.2007.04547.x
- The paper
- Hong, X. Z., Li, L. D., & Wu, L. M. (2007). EFFECTS OF FENOFIBRATE AND XUEZHIKANG ON HIGH‐FAT DIET‐INDUCED NON‐ALCOHOLIC FATTY LIVER DISEASE. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/j.1440-1681.2007.04547.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.